Zhiqiang Wu

No. 58 Zhongshan 2 Road
Guangzhou, 510080, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 43 publications

HAIC combined with lenvatinib and tislelizumab for HCC with concurrent PVTT and pulmonary metastasis: a multicenter propensity score matching analysis.

HAIC combined with lenvatinib and tislelizumab for HCC with concurrent PVTT and pulmonary metastasis: a multicenter propensity score matching analysis.

Journal: Therapeutic advances in medical oncology

Published: April 13, 2026

Unveiling the oncogenic role of lncRNA PIG13-DT in hepatocellular carcinoma progression.

Unveiling the oncogenic role of lncRNA PIG13-DT in hepatocellular carcinoma progression.

Journal: Cancer biology & therapy

Published: October 09, 2025

High-entropy Mn-Prussian blue analogues enable long-term cycling in aqueous sodium-ion batteries through synergistic redox and ion diffusion enhancements.

High-entropy Mn-Prussian blue analogues enable long-term cycling in aqueous sodium-ion batteries through synergistic redox and ion diffusion enhancements.

Journal: Journal of colloid and interface science

Published: September 24, 2025

Development and evaluation of a predictive model based on multi-frequency magnetic resonance elastography for high-risk esophagogastric varices in patients with cirrhotic portal hypertension.

Development and evaluation of a predictive model based on multi-frequency magnetic resonance elastography for high-risk esophagogastric varices in patients with cirrhotic portal hypertension.

Journal: Insights into imaging

Published: May 03, 2025

Bilayer Mn-based Prussian blue cathode with high redox activity for boosting stable cycling in aqueous sodium-ion half/full batteries.

Bilayer Mn-based Prussian blue cathode with high redox activity for boosting stable cycling in aqueous sodium-ion half/full batteries.

Journal: Journal of colloid and interface science

Published: December 03, 2024

Lenvatinib and tislelizumab versus atezolizumab and bevacizumab in combination with TAE-HAIC for unresectable hepatocellular carcinoma with high tumor burden: a multicenter retrospective cohort study.

Lenvatinib and tislelizumab versus atezolizumab and bevacizumab in combination with TAE-HAIC for unresectable hepatocellular carcinoma with high tumor burden: a multicenter retrospective cohort study.

Journal: Cancer immunology, immunotherapy : CII

Published: November 20, 2024

An integrated pathway mutation and clinical model predicts survival in unresectable HCC with hepatic arterial infusion chemotherapy combined with lenvatinib and tislelizumab.

An integrated pathway mutation and clinical model predicts survival in unresectable HCC with hepatic arterial infusion chemotherapy combined with lenvatinib and tislelizumab.

Journal: BMC cancer

Published: September 27, 2024

HAIC plus lenvatinib and tislelizumab for advanced hepatocellular carcinoma with Vp4 portal vein invasion.

HAIC plus lenvatinib and tislelizumab for advanced hepatocellular carcinoma with Vp4 portal vein invasion.

Journal: Hepatology international

Published: September 09, 2024

Factors associated with dysmenorrhoea and menorrhagia improvement in patients with adenomyosis after uterine artery embolisation.

Factors associated with dysmenorrhoea and menorrhagia improvement in patients with adenomyosis after uterine artery embolisation.

Journal: Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology

Published: June 29, 2024

Efficacy of Outside-In Hip Arthroscopy without Traction in the Treatment of Hip Synovial Osteochondromatosis.

Efficacy of Outside-In Hip Arthroscopy without Traction in the Treatment of Hip Synovial Osteochondromatosis.

Journal: Orthopaedic surgery

Published: May 16, 2024

TACE plus lenvatinib and tislelizumab for intermediate-stage hepatocellular carcinoma beyond up-to-11 criteria: a multicenter cohort study.

TACE plus lenvatinib and tislelizumab for intermediate-stage hepatocellular carcinoma beyond up-to-11 criteria: a multicenter cohort study.

Journal: Frontiers in immunology

Published: May 10, 2024

Identification of prognostic tumor microenvironment in patients with advanced hepatocellular carcinoma treated with hepatic arterial infusion chemotherapy combined with lenvatinib and PD-1 inhibitors.

Identification of prognostic tumor microenvironment in patients with advanced hepatocellular carcinoma treated with hepatic arterial infusion chemotherapy combined with lenvatinib and PD-1 inhibitors.

Journal: International immunopharmacology

Published: April 30, 2024

Showing 1-12 of 43

Last Updated: 09/26/2026